Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1987 articles with Sanofi (France)
-
Pfizer, J&J and GSK indicate plans to file for regulatory approval by the end of this year for vaccines against RSV, which would see vaccines against the disease becoming available in 2023.
-
Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
4/14/2022
Positive results from the Phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, in adults with heavily pre-treated immune thrombocytopenia were published in the New England Journal of Medicine.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
-
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
4/7/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has expanded the marketing authorization for Dupixent® in the European Union.
-
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
4/7/2022
The European Commission has expanded the marketing authorization for Dupixent® in the European Union.
-
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
4/4/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis, a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
-
Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
4/4/2022
Sanofi launches its Diversity, Equity & Inclusion Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors.
-
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022
4/1/2022
Sanofi announced that the French Autorité des marchés financiers has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.
-
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson's pay had a drop of about 3.7%, according to the company’s annual filing.
-
Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines
3/31/2022
Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes.
-
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes
3/30/2022
Sanofi announced that its Q1 2022 Memorandum for modelling purposes is available on the "Investors" page of the company's website:.
-
Sanofi and IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.
-
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
3/29/2022
Sanofi will host an Immunology Investor Event with key members of the leadership team providing updates on how the company is advancing its Immunology strategy, including the ambition to more than quadruple Immunology franchise sales by the end of the decade.
-
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
3/29/2022
Sanofi and IGM Biosciences, Inc. announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets.
-
IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi
3/29/2022
IGM Biosciences, Inc. announced that the Company will host a conference call and live audio webcast, Tuesday, March 29, 2022, at 8:00 am ET to discuss the Company’s global collaboration agreement with Sanofi, as recently announced.
-
IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/29/2022
IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent developments.
-
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency
3/28/2022
The Japanese Ministry of Health, Labor, and Welfare has granted marketing authorization for Xenpozyme® for the treatment of adult and pediatric patients with non-central nervous system manifestations of acid sphingomyelinase deficiency, a rare, progressive, and potentially life-threatening genetic disease.
-
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
3/26/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced that detailed positive results from the Phase 3 PRIME2 trial evaluating the efficacy and safety of Dupixent® were presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.
-
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
3/26/2022
Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent® was presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.